Anna Comstock
Family · Shelbyville, INNPI 1508407131
Payments from drug & device makers
Across 225 payments — averaging $16.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Supernus Pharmaceuticals, Inc.$328
- Novo Nordisk$223
- Boehringer Ingelheim$216
- Pfizer$155
- Amgen$144
- plus $1K from 33 others
What the payments were for
- Food & beverage$3,644100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$143
How this compares
$3,644 in reported general payments places this provider in the 85th percentile of 4,392 family providers in Indiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 109 | $128,914 |
| JardianceEmpagliflozin | 49 | $67,440 |
| FarxigaDapagliflozin Propanediol | 56 | $59,728 |
| TrulicityDulaglutide | 44 | $53,154 |
| Repatha SureclickEvolocumab | 54 | $35,874 |
| VraylarCariprazine Hcl | 18 | $35,369 |
| MounjaroTirzepatide | 30 | $30,555 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $25,426 |
| EliquisApixaban | 18 | $25,229 |
| LinzessLinaclotide | 12 | $11,463 |
| VascepaIcosapent Ethyl | 21 | $10,845 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 18 | $9,846 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $8,290 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 27 | $5,296 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 33 | $4,510 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $223 | $128,914109 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $96 | $83,70974 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $216 | $77,28667 claims |
| AstraZenecaFarxiga | $49 | $59,72856 claims |
| AbbVieVraylar, Linzess | $1,100 | $46,83230 claims |
| PfizerEliquis | $155 | $25,22918 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,392 family providers in Indiana.
Other family in Shelbyville
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
- Lacey MatheisEvansville$139K
- Myra SikwataHobart$131K
- Elizabeth JohnsonEvansville$108K
- Beverly MaugerFt Wayne$94K
- Nancy ArndtPortage$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.